MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until this upcoming Monday,...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.